Heart failure management is evolving rapidly. The introduction of quad-therapy protocols (including ARNIs, Beta-Blockers, MRA, and SGLT2 inhibitors) has shown outstanding clinical efficacy when initiated early in patients with reduced ejection fraction (HFrEF).
Quad-Therapy Implementation
Rather than traditional sequential optimization, modern guidelines recommend rapid initiation and titration of all four pillars within 4 to 6 weeks. This has demonstrated immediate benefits in terms of mortality reduction and quality of life improvement.
